Rethinking Clinical Trials

SEPTEMBER 28, 2023

In the initial PARENT trial, intervention families had better performance on receipt of well child care, and patients reported better patient experience and fewer emergency department visits. How might we better structure preventive visits? Adapted for early childhood preventive care, the structure should be team- and community-based.

Trials 269

Trials Clinical Trials Clinical Trials Research 269

Rethinking Clinical Trials

AUGUST 23, 2022

Participating organizations included FDA, NIH, academic institutions, pharmaceutical and device companies, patient advocacy groups, community groups, and data groups, and representatives from each organization had opportunity to extend invitation to others. population at large, which is steadily becoming more diverse. Discussion Themes. -Is

Clinical Trials 130

Clinical Trials Clinical Trials Trials Medicine 130

Rethinking Clinical Trials

AUGUST 22, 2022

Patients with diabetes or prediabetes were not excluded (except for those on insulin or sulfonylurea); pregnant patients were not excluded for the Metformin arm; the trial restricted participants to people who were overweight or obese to enrich the population for having a high risk of outcomes and for anti-inflammatory hypotheses around Metformin.

Trials 130

Trials Clinical Trials Clinical Trials Insulin 130

Rethinking Clinical Trials

SEPTEMBER 30, 2022

The home visit services were covered through a Medicaid waiver that allowed the Nurse Family Partnership (NFP) to serve about 4,000 people over 4 years (up to 40 visits at home). Margaret McConnell, PhD. Associate Professor. Department of Global Health and Population. Harvard T.H. Chan School of Public Health. Randomized controlled trial.

Nurses 130

Nurses Trials Clinical Trials Clinical Trials 130

XTalks

APRIL 18, 2024

Conversely, a negative result suggests a low probability of amyloid pathology, guiding healthcare providers in clinical decision-making and potentially ruling out Alzheimer’s disease in symptomatic patients. There are currently no FDA-authorized blood tests for detecting Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

The Pharma Data

AUGUST 18, 2020

Dragonfly CEO and co-Founder Bill Hanley said of the deal: “We are confident that the talent, experience and commitment to science-driven innovation of the Bristol Myers Squibb team will enable DF6002 to discover novel, lifesaving solutions for patients.”. Matt Fellows. Source link.

Protein 52

Protein Sales Drugs 52

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Virtual connections. Engagement channels.

Regulation 79

Regulation Marketing Sales Branding 79

pharmaphorum

SEPTEMBER 15, 2020

The huge rise in the use of telemedicine services during lockdown has brought care directly to patients in their homes, while pharma’s communications with healthcare professionals (HCPs) has experienced a similar push to digital channels.

Branding 106

Branding Marketing Pharma Companies Life Science 106

pharmaphorum

JANUARY 21, 2022

It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance. Flawed funding model.

Medicine 52

Medicine Marketing Manufacturing Production 52

XTalks

JUNE 9, 2021

The historic and highly anticipated approval created a flurry of excitement in the Alzheimer’s disease space for patients, healthcare practitioners, advocacy groups and Biogen shareholders alike, as shares of the company jumped more than 50 percent after the announcement. Aducanumab Controversy and Price Tag.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

Delveinsight

FEBRUARY 9, 2021

The move came not long after healthcare investor giant Deerfield Management has forged a partnership to create the Center for Protein Degradation, investing worth USD 80 million. Deerfield and Dana-Farber Establish Links in USD 130 Million Cancer Research Deal. The funding will help to create and launch Riverway Discoveries.

FDA Approval 52

FDA Approval Marketing Research Protein 52

The Pharma Data

OCTOBER 9, 2021

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies. Roche’s Chief Medical Officer and Head of Global Product Development.

Antibody 52

Antibody In-Vitro Trials Development 52

XTalks

FEBRUARY 27, 2024

Skyclarys (omobaloxone) was approved in 2023 for the treatment of adults and pediatric patients 16 years of age and older with Friedreich’s ataxia, a rare, neurological disease​​. The US Food and Drug Administration (FDA) has approved a number of new rare disease drugs in recent years, including gene therapies.

Research 59

Research Drugs Gene Therapy Clinical Trials 59

pharmaphorum

JUNE 15, 2021

The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways and public-private partnerships drive innovation to address a common need. A new economic reality is challenging profitability . billion and $6.7

Clinical Trials 89

Clinical Trials Clinical Trials Development Marketing 89

pharmaphorum

FEBRUARY 26, 2021

Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a strong pharmaceutical backbone that has emerged over the company’s long and varied history. Johnson & Johnson was founded over 125 years ago in the year 1886. Where it all began.

Sales 116

Sales Production Pharma Companies Marketing 116

XTalks

MARCH 22, 2023

To celebrate this milestone, we’re taking a look back over the last 20 years in the pharmaceutical industry by highlighting some of the most talked-about mergers, blockbuster drugs, trends in FDA approvals and what’s next. And make sure you’re registered for our free online community for instant access to thousands of on-demand webinars.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Rethinking Clinical Trials

OCTOBER 31, 2023

The research optimization requires partnership with participants, including involvement in study design and workflow, data collection and analysis, and data and results sharing. Does it capture most what matters to patients? Research can improve by simultaneously leveraging advances in technology and culture. Pfizer provided feedback.

Trials 228

Trials Medicine Research Clinical Trials 228